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Clinical Question 
What is the most effective oral monotherapy for glycemic control in patients with type 2 
diabetes? 
Evidence-Based Answer 
There is no clearly superior oral agent for glycemic control in patients with type 2 diabetes. 
(Strength of Recommendation [SOR]: C) 
Metformin (Glucophage) has shown additional benefit when compared with other treatments 
(including insulin) for diabetes-related outcomes and all-cause mortality and should be 
considered the agent of choice for initial monotherapy, particularly in obese patients. (SOR: A) 
Evidence Summary 
A systematic review of 63 randomized controlled trials (RCTs) compared A1C reductions among 
the five classes of oral agents.1 The studies met the following criteria: study period of at least 
three months, enrollment of at least 10 subjects, and reported A1C reduction. Two groups of 
trials-monotherapy head-to-head studies (23 trials) and monotherapy versus placebo studies (31 
trials)-were compared. A1C reductions were similar among studies with comparable numbers of 
subjects and lengths of follow-up (Table 11). Head-to-head trials comparing two or more drugs 
also showed similar effectiveness for reducing A1C.1 
Table 1. Clinical Trials of Monotherapy for Glycemic Control in Patients with Type 
2 Diabetes 
Medication class (number of 
trials) Study length 
Number of 
subjects 
Ranges of A1C 
reductions (%) 
Sulfonylurea (4) 12 weeks to 10 
years 
204 to 3,867 0.9 to 2.5 
Alpha glucosidase inhibitor 16 weeks to 2 40 to 495 0.4 to 1.3 
(12) years 
Metformin (7) 11 weeks to 
10.7 years 
27 to 753 0.8 to 3.0 
Meglitinide (4) 12 to 24 weeks 93 to 701 0.6 to 1.7 
Thiazolidinedione (4) 24 to 26 weeks 402 to 959 1.1 to 1.6 
 
Information from Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: 
scientific review. JAMA 2002;287:360-72. 
The United Kingdom Prospective Diabetes Study included 4,075 newly diagnosed patients with 
type 2 diabetes who had A1C levels of 7.5 to 10.7 percent.2 After three months of diet therapy, 
subjects were randomized to four groups: insulin, sulfonylurea, metformin, or continued diet 
therapy. Only 50 percent of the patients in any group had A1C levels of less than 7 percent after 
three years, and only 25 percent had levels of less than 7 percent after nine years.2 
Glycemic control is not the ultimate goal of diabetes treatment; the focus should be on which 
medications best reduce morbidity and mortality. A Cochrane review that included 29 trials and 
5,259 participants looked at intensive glucose control with metformin.3 Metformin showed 
greater benefits for all-cause mortality (P = .03) and diabetes-related outcomes (P = .009) when 
compared with sulfonylurea, placebo, diet, thiazolidinedione, insulin, meglitinides, and 
glucosidase inhibitors.3 
A systematic review of alpha-glucosidase inhibitors found no clear evidence that they reduce 
morbidity or mortality.4 
Recommendations from Others 
The American Diabetes Association recommends that patients with type 2 diabetes maintain an 
A1C of less than 7 percent. They do not recommend any specific medications for therapy.5 
The Institute for Clinical Systems Improvement reports that the single best choice for oral 
therapy for type 2 diabetes has not been determined.6 The guideline also states that the United 
Kingdom Prospective Diabetes Study provides strong evidence that metformin in monotherapy 
may offer advantages for obese patients with type 2 diabetes with respect to morbidity and 
mortality. The guideline aconsiders sulfonylurea a good choice for monotherapy because it is 
relatively inexpensive and generally well tolerated.6 
Clinical Commentary 
Oral therapy for diabetes has long been an issue of "This is how I was trained" for physicians. 
Early on, sulfonylureas were the only choice. When metformin arrived on the scene in the 1990s, 
it brought more choice, and with the introduction of thiazolidinediones, meglitinides, and 
glucosidase inhibitors, the situation is even less clear. Achieving glucose and A1C goals remains 
one of the aims of diabetic therapy, but the bottom line should be reduction in morbidity and 
mortality. 
Monotherapy with metformin is therefore appealing for several reasons: (1) it is generally well 
tolerated and its side effects are usually easy to manage; (2) the risk of hypoglycemia is minimal; 
and (3) it has direct effects on insulin resistance. With evidence of benefit in total morbidity and 
mortality over other oral antidiabetic agents, metformin seems a good choice for monotherapy 
when a single agent is effective. 
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